FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably ...

Fosamax further defines the obligation of drug manufacturers to present clear, unambiguous, and accurate information to the ...

New Delhi, has established a dedicated committee to monitor and report adverse events related to drugs and medical devices ...